JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Pexacerfont (formerly known as BMS-562086) is a novel potent, selective and orally bioactive antagonist of corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1+/-0.6 nM for human CRF1 receptor. Pexacerfont is currently in clinical trials for the treatment of anxiety disorders, and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome. BMS-562086 exhibited favorable ADME and pharmacokinetic properties for further development.
References: Drug Metab Dispos. 2012 Jun; 40(6):1093-103.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!